Naselsky W - Search Results

1

Non-intensive care unit feasibility for ambulatory veno-venous extracorporeal membrane oxygenation patients.

Shah A, Stachnik S, Leibowitz JL, Ramadan L, Ejimogu J, Singireddy S, Naselsky W, Grazioli A, Rabin J, Wu ZJ, Griffith BP. Shah A, et al. Among authors: naselsky w. Perfusion. 2024 Nov 23:2676591241302959. doi: 10.1177/02676591241302959. Online ahead of print. Perfusion. 2024. PMID: 39579011

2

Commentary on: Risk of prolonged ischaemic time linked to use of cardio-pulmonary bypass during implantation for lung transplantation in the United Kingdom.

Naselsky WC, Lau CL, Krupnick AS. Naselsky WC, et al. J Heart Lung Transplant. 2023 Oct;42(10):1397-1398. doi: 10.1016/j.healun.2023.06.004. Epub 2023 Jun 15. J Heart Lung Transplant. 2023. PMID: 37330118 No abstract available.

3

Pneumothorax in acute respiratory distress syndrome on extracorporeal membrane oxygenation support.

Shah A, Naselsky W, Dave S, Young BA, Bittle G, Tabatabai A, Friedberg J, Krause E. Shah A, et al. Among authors: naselsky w. Perfusion. 2024 May;39(4):776-783. doi: 10.1177/02676591231159559. Epub 2023 Mar 6. Perfusion. 2024. PMID: 36877783

4

Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation.

Adhikary G, Shrestha S, Naselsky W, Newland JJ, Chen X, Xu W, Emadi A, Friedberg JS, Eckert RL. Adhikary G, et al. Among authors: naselsky w. Mol Carcinog. 2023 Apr;62(4):438-449. doi: 10.1002/mc.23497. Epub 2022 Dec 23. Mol Carcinog. 2023. PMID: 36562471 Free PMC article.

5

Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotype.

Chen X, Adhikary G, Ma E, Newland JJ, Naselsky W, Xu W, Eckert RL. Chen X, et al. Among authors: naselsky w. Mol Carcinog. 2023 Feb;62(2):236-248. doi: 10.1002/mc.23479. Epub 2022 Oct 26. Mol Carcinog. 2023. PMID: 36285644 Free PMC article.

6

The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.

Chen X, Adhikary G, Newland JJ, Xu W, Ma E, Naselsky W, Eckert RL. Chen X, et al. Among authors: naselsky w. Mol Carcinog. 2023 Jan;62(1):90-100. doi: 10.1002/mc.23446. Epub 2022 Jul 18. Mol Carcinog. 2023. PMID: 35848131 Free PMC article.

7

Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype.

Naselsky W, Adhikary G, Shrestha S, Chen X, Ezeka G, Xu W, Friedberg JS, Eckert RL. Naselsky W, et al. Mol Carcinog. 2022 Jun;61(6):537-548. doi: 10.1002/mc.23399. Epub 2022 Mar 23. Mol Carcinog. 2022. PMID: 35319795 Free PMC article.

8

ACTL6A suppresses p21^Cip1 tumor suppressor expression to maintain an aggressive mesothelioma cancer cell phenotype.

Shrestha S, Adhikary G, Naselsky W, Xu W, Friedberg JS, Eckert RL. Shrestha S, et al. Among authors: naselsky w. Oncogenesis. 2021 Oct 23;10(10):70. doi: 10.1038/s41389-021-00362-7. Oncogenesis. 2021. PMID: 34689163 Free PMC article.

9

Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype.

Chen X, Adhikary G, Shrestha S, Xu W, Keillor JW, Naselsky W, Eckert RL. Chen X, et al. Among authors: naselsky w. Mol Cancer Res. 2021 Dec;19(12):2026-2035. doi: 10.1158/1541-7786.MCR-21-0306. Epub 2021 Sep 30. Mol Cancer Res. 2021. PMID: 34593609 Free PMC article.

10

Limited Left Thoracoscopic Sympathectomy Effectively Silences Refractory Electrical Storm.

Krause EM, Appelbaum J, Naselsky W, Dickfeld T, Friedberg J, See V, Burrows W. Krause EM, et al. Among authors: naselsky w. Ann Thorac Surg. 2022 Jan;113(1):217-223. doi: 10.1016/j.athoracsur.2021.01.039. Epub 2021 Feb 2. Ann Thorac Surg. 2022. PMID: 33545155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters